Key result
A trial evaluating enoxaparin versus aspirin in patients with cancer and ischemic stroke removed exclusion criteria after study initiation to increase patient recruitment.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Mid-study exclusion criteria changes risk confounding results; leaves open optimal antithrombotic strategy in cancer-associated stroke pending rigorous trials.
Trial b Exclusion criteria were removed after study initiation to increase patient recruitment.
No takes yet. Share an insight, caveat, or question.
Navi et al. (2018) studied this question. A trial evaluating enoxaparin versus aspirin in patients with cancer and ischemic stroke removed exclusion criteria after study initiation to increase patient recruitment.
Synapse has enriched 10 related papers. Consider them for comparative context: